Figure 1.

Infant r-hFSH treatment responses and long-term outcomes in three boys with congenital hypogonadotropic hypogonadism (CHH). The lines represent individual inhibin B levels in three patients with CHH (patients #3 to #5 in Tables II, III and V). Recombinant hFSH [r-hFSH] treatment, shown in thickened lines for each patient, was initiated at the age of 0.2 ± 0.1 years: r-hFSH was administered at 3.4 IU/kg to 7.5 IU/kg s.c. per week in two to three doses for 3–4.5 months and testosterone was administered at 25 mg i.m. once a month for three months. Panel A describes the first year of life of these three treated boys, and panel B the development of their inhibin B values after the age of 9 years. The red dots in panel B mark inhibin B values of eight boys in an untreated CHH and CPHD control group (Table IV, Varimo et al., 2017; Kohva et al., 2018). The beige box in panel B represents, as a reference, the range of inhibin B in 29 healthy prepubertal boys with idiopathic short stature aged between 9.1 and 13.9 years in stage G1 with testicular volume below 2 mL (Hero et al., 2005)